Syntara (ASX:SNT) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Syntara Days Payable?

Syntara's average Accounts Payable for the six months ended in Dec. 2024 was A$1.45 Mil. Syntara's Cost of Goods Sold for the six months ended in Dec. 2024 was A$0.00 Mil.

The historical rank and industry rank for Syntara's Days Payable or its related term are showing as below:

During the past 13 years, Syntara's highest Days Payable was 148.17. The lowest was 148.17. And the median was 148.17.

ASX:SNT's Days Payable is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 85.85
* Ranked among companies with meaningful Days Payable only.

Syntara's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

Syntara Days Payable Historical Data

The historical data trend for Syntara's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara Days Payable Chart

Syntara Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Days Payable

Get a 7-Day Free Trial

148.17

Syntara Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Days Payable	Get a 7-Day Free Trial															350.04	250.57	-	-	-

Competitive Comparison of Syntara's Days Payable

For the Drug Manufacturers - Specialty & Generic subindustry, Syntara's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syntara's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syntara's Days Payable distribution charts can be found below:

* The bar in red indicates where Syntara's Days Payable falls into.

Save Embed

;

Save Embed

;

Syntara Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Syntara's Days Payable for the fiscal year that ended in Jun. 2024 is calculated as

	Days Payable (A: Jun. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2023 )	+	Accounts Payable (A: Jun. 2024 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2024 )	*	Days in Period
=	( (1.582	+	0.614)	/	2 )	/	0	*	365
=	1.098					/	0	*	365
=	N/A

Syntara's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (0.614	+	2.276)	/	2 )	/	0	*	365 / 2
=	1.445					/	0	*	365 / 2
=	N/A

Syntara Days Payable Related Terms

Thank you for viewing the detailed overview of Syntara's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Syntara Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

UUDA:Germany

Address

20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.syntaratx.com.au

Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.